ARCHIVES

U.S., Canada Begin ExCel Trial To Evaluate Aromasin For Breast Cancer Prevention

This article is from The Cancer Letter archive.

Vol. 28 No. 4 | April 29, 2005

Download PDF Visit The Full Archive

Related Articles

NIH grant success rate drops to under 20 percent after 2011 budget cuts

May 13, 2011

ColoPrint Improves Prognosis In Stage II and III Colon Cancer

January 28, 2011

Continuing Progress Reported On Breast Cancer Treatment; Mammography Controversy Cooled

November 26, 1976

Hope for FDA authority over tobacco products dies in Congress.

October 15, 2004

AVEO’s Tivozanib Sunk by Fundamental Flaw: Higher Overall Survival in the Control Arm

May 8, 2013

Study: Prostate Cancer Classifier Can Predict Risk Better Than PSA, Gleason Score, Tumor Stage

February 28, 2014